Cargando…

Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis

BACKGROUND: The causes for nonadherence to mesalamine in patients with inflammatory bowel disease (IBD) have been characterized using mostly indirect methods. Patient-reported barriers are lacking in this population. OBJECTIVES: To identify patient-reported barriers to mesalamine adherence through d...

Descripción completa

Detalles Bibliográficos
Autores principales: Devlen, Jennifer, Beusterien, Kathleen, Yen, Linnette, Ahmed, Awais, Cheifetz, Adam S., Moss, Alan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437525/
https://www.ncbi.nlm.nih.gov/pubmed/24564811
http://dx.doi.org/10.18553/jmcp.2014.20.3.309
_version_ 1785092545259241472
author Devlen, Jennifer
Beusterien, Kathleen
Yen, Linnette
Ahmed, Awais
Cheifetz, Adam S.
Moss, Alan C.
author_facet Devlen, Jennifer
Beusterien, Kathleen
Yen, Linnette
Ahmed, Awais
Cheifetz, Adam S.
Moss, Alan C.
author_sort Devlen, Jennifer
collection PubMed
description BACKGROUND: The causes for nonadherence to mesalamine in patients with inflammatory bowel disease (IBD) have been characterized using mostly indirect methods. Patient-reported barriers are lacking in this population. OBJECTIVES: To identify patient-reported barriers to mesalamine adherence through direct interviews. METHODS: Focus groups and one-on-one interviews were undertaken in adult patients with IBD. Transcripts from the focus groups and interviews were analyzed to identify themes and links between these themes, assisted by qualitative data software MaxQDA. RESULTS: Of 27 patients participating, 21 (78%) had ulcerative colitis, and 6 (22%) had Crohn’s disease. Their self-reported adherence ranged from complete adherence (n = 3) to intermittent nonadherence (n = 24). Patients frequently indicated that they were resistant to taking medications for their condition. The barriers to adherence that emerged from interviews could be categorized under a number of themes: competing priorities, social stigma, refill inconvenience, costs, efficacy values, side effects, and pill characteristics. Efficacy values reported to influence adherence included doubts about efficacy, consequences of missed doses, and doubts about need for maintenance medication. Pill characteristics reported as barriers included pill size and pill frequency. Despite use of electronic prescribing, obtaining refills was reported as an obstacle to adherence in this cohort. Decanting of pills to multiple containers to increase accessibility was also reported. CONCLUSIONS: Patients with both ulcerative colitis and Crohn’s disease report a number of common barriers to mesalamine adherence. Factors in medication-taking behavior and beliefs were reported in this study that may have implications for strategies to improve adherence by health care providers.
format Online
Article
Text
id pubmed-10437525
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104375252023-08-21 Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis Devlen, Jennifer Beusterien, Kathleen Yen, Linnette Ahmed, Awais Cheifetz, Adam S. Moss, Alan C. J Manag Care Pharm Research BACKGROUND: The causes for nonadherence to mesalamine in patients with inflammatory bowel disease (IBD) have been characterized using mostly indirect methods. Patient-reported barriers are lacking in this population. OBJECTIVES: To identify patient-reported barriers to mesalamine adherence through direct interviews. METHODS: Focus groups and one-on-one interviews were undertaken in adult patients with IBD. Transcripts from the focus groups and interviews were analyzed to identify themes and links between these themes, assisted by qualitative data software MaxQDA. RESULTS: Of 27 patients participating, 21 (78%) had ulcerative colitis, and 6 (22%) had Crohn’s disease. Their self-reported adherence ranged from complete adherence (n = 3) to intermittent nonadherence (n = 24). Patients frequently indicated that they were resistant to taking medications for their condition. The barriers to adherence that emerged from interviews could be categorized under a number of themes: competing priorities, social stigma, refill inconvenience, costs, efficacy values, side effects, and pill characteristics. Efficacy values reported to influence adherence included doubts about efficacy, consequences of missed doses, and doubts about need for maintenance medication. Pill characteristics reported as barriers included pill size and pill frequency. Despite use of electronic prescribing, obtaining refills was reported as an obstacle to adherence in this cohort. Decanting of pills to multiple containers to increase accessibility was also reported. CONCLUSIONS: Patients with both ulcerative colitis and Crohn’s disease report a number of common barriers to mesalamine adherence. Factors in medication-taking behavior and beliefs were reported in this study that may have implications for strategies to improve adherence by health care providers. Academy of Managed Care Pharmacy 2014-03 /pmc/articles/PMC10437525/ /pubmed/24564811 http://dx.doi.org/10.18553/jmcp.2014.20.3.309 Text en Copyright © 2014, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research
Devlen, Jennifer
Beusterien, Kathleen
Yen, Linnette
Ahmed, Awais
Cheifetz, Adam S.
Moss, Alan C.
Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis
title Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis
title_full Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis
title_fullStr Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis
title_full_unstemmed Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis
title_short Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis
title_sort barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437525/
https://www.ncbi.nlm.nih.gov/pubmed/24564811
http://dx.doi.org/10.18553/jmcp.2014.20.3.309
work_keys_str_mv AT devlenjennifer barrierstomesalamineadherenceinpatientswithinflammatoryboweldiseaseaqualitativeanalysis
AT beusterienkathleen barrierstomesalamineadherenceinpatientswithinflammatoryboweldiseaseaqualitativeanalysis
AT yenlinnette barrierstomesalamineadherenceinpatientswithinflammatoryboweldiseaseaqualitativeanalysis
AT ahmedawais barrierstomesalamineadherenceinpatientswithinflammatoryboweldiseaseaqualitativeanalysis
AT cheifetzadams barrierstomesalamineadherenceinpatientswithinflammatoryboweldiseaseaqualitativeanalysis
AT mossalanc barrierstomesalamineadherenceinpatientswithinflammatoryboweldiseaseaqualitativeanalysis